Key facts
- This page summarizes Bruce I. Sachs's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 May 2022, 16:43.
Bruce I. Sachs - 01 May 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)
- Reporting relationship
- Director
- Issuer ticker
- VRTX
- Reported as of
- 01 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 May 2022, 16:43:02 UTC
- Prior SEC filing
- 18 Apr 2022
- Next SEC filing
- 19 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sabrina Yohai, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bruce I. Sachs filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 03 May 2022.
Change
- Previous filing in this sequence was filed on 18 Apr 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +4,462
- Change %
- Price
- $0.000000
- Shares after
- 4,462
- Date
- 01 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,462
- Exercise price
- $276.17
* marks a reported price that did not pass the local price check.